Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis

Abstract

The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant. According to the present invention, the alkaline arsenous acid metal salt is sodium meta-arsenita (AsO 2 Na) or potassium meta-arsenite (AsO 2 K). The effective amount of arsenous acid alkaline or earth alkaline metal salt is 0.0001-1500 mg/kg, preferably 1-1000 mg/kg, more preferably 1-150 mg/kg, and most preferably 50-100 mg/kg of body weight/day. The administration form of the pharmaceutical compositions of the invention is preferably oral, such as a tablet, capsule, powder and/or solution with a pharmaceutically acceptable carrier, diluent or excipient.

1 - 6 . (canceled) 
     
     
         7 . A method of treating metastatic cancer in a patient, comprising administering a composition comprising a therapeutically effective amount of a sodium meta arsenite to the patient. 
     
     
         8 . A method of treating melanoma, central nervous system or lung cancer in a patient, comprising administering a composition comprising a therapeutically effective amount of sodium meta arsenite to the patient. 
     
     
         9 . (canceled) 
     
     
         10 . A method of treating metastatic cancer in a patient, comprising administering a composition comprising a therapeutically effective amount of sodium meta arsenite to the patient. 
     
     
         11 . A method of  claim 10  wherein said metastatic cancer is cancer of the epithelial tissue, lymphoid tissue, connective tissue, bone or central nervous system. 
     
     
         12 . A method of  claim 11  wherein said metastatic cancer is a squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, colorectal carcinoma or gastric carcinoma. 
     
     
         13 . A method of  claim 11  wherein said metastatic cancer is a tumour of epithelial glands, epithelial ducts, liver, biliary tract, gastrointestinal tract, respiratory tract or urogenital tract. 
     
     
         14 . A method of  claim 11  wherein said metastatic cancer is Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, diffuse lymphoma, lymphoblastic lymphoma, large cell lymphoma or small cell lymphoma. 
     
     
         15 . A method of  claim 11  wherein said metastatic cancer is selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma or oligodendroglioma 
     
     
         16 - 19 . (canceled) 
     
     
         20 . The method of  claim 7  wherein the pharmaceutical composition further comprises a non-arsenic anti-cancer agent. 
     
     
         21 . The method of  claim 20  wherein the patient has lung cancer.